Your browser doesn't support javascript.
loading
Biomarker research for moyamoya disease in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Maruwaka, Mikio; Yoshikawa, Kazuhiro; Okamoto, Sho; Araki, Yoshio; Sumitomo, Masaki; Kawamura, Akino; Yokoyama, Kinya; Wakabayashi, Toshihiko.
Afiliação
  • Maruwaka M; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: maruwakamikio@gmail.com.
  • Yoshikawa K; Division of Advanced Research Promotion Institute of Comprehensive Medical Research, Nagakute-City, Japan; Division of Advanced Medicine Advanced Medical Research Center; Laboratory of Cell Therapy Division of Advanced Medical Research Center.
  • Okamoto S; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Araki Y; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Sumitomo M; Department of Neurosurgery, Komaki Municipal Hospital, Komaki-City, Japan.
  • Kawamura A; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Yokoyama K; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Wakabayashi T; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
J Stroke Cerebrovasc Dis ; 24(1): 104-11, 2015 Jan.
Article em En | MEDLINE | ID: mdl-25440344
ABSTRACT
Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by steno-occlusive change in bilateral internal carotid arteries with unknown etiology. To discover biomarker candidates in cerebrospinal fluid from MMD patients, proteome analysis was performed by the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Three peptides, 4473Da, 4475Da, and 6253Da, were significantly elevated in MMD group. A positive correlation between 4473Da peptide and postoperative angiogenesis was determined. Twenty MMD patients were enrolled in this pilot study, including 11 pediatric cases less than 18 years of age (mean age, 8.67 years) and 9 adult MMD patients (mean age, 38.1 years). This study also includes 17 control cases with the mean age of 27.9 years old. In conclusion, 4473Da peptide is supposed to be a reliable biomarker of MMD. 4473Da peptide showed higher intensity peaks especially in younger MMD patients, and it was proved to be highly related to postoperative angiogenesis. Further study is needed to show how 4473Da peptide is involved with the etiology and the onset of MMD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz / Doença de Moyamoya Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz / Doença de Moyamoya Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article